Alnylam Pharmaceuticals
ALNY
476 hedge funds and large institutions have $22.5B invested in Alnylam Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 163 increasing their positions, 156 reducing their positions, and 54 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
4% more repeat investments, than reductions
Existing positions increased: 163 | Existing positions reduced: 156
2% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 54
0% more funds holding
Funds holding: 476 → 476 (0)
1.12% less ownership
Funds ownership: 96.36% → 95.24% (-1.1%)
6% less capital invested
Capital invested by funds: $24B → $22.5B (-$1.43B)
26% less call options, than puts
Call options by funds: $119M | Put options by funds: $162M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$129M |
| 2 |
Morgan Stanley
New York
|
+$129M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$83.7M |
| 4 |
Bank of New York Mellon
New York
|
+$43.9M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$162M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$134M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$83M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$50.4M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$49M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BWM
526
BerganKDV Wealth Management
Bloomington,
Minnesota
| – | -$401 | -2 | Closed |
|
527
Optiver Holding
Amsterdam,
Netherlands
| – | -$401 | -2 | Closed |
|
|
PTC
528
Private Trust Company
Cleveland,
Ohio
| – | -$200 | -1 | Closed |
|
|
AW
529
Avion Wealth
The Woodlands,
Texas
| – | +$595 | +3 | New |
|
ALNY Hedge Fund Activity: Q2 2023 in Review
476 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2023, worth a combined $22.5B — down 6% from $24B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new ALNY positions and 54 closed out — a net gain of 1 holder — while 163 added to existing stakes and 156 trimmed.
The largest buyer was Capital International Investors, adding an estimated $129M. The largest seller was Norges Bank, cutting an estimated $162M.
- 476 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $22.5B of Alnylam Pharmaceuticals stock for Q2 2023, down 6% quarter-over-quarter.
- 55 funds opened new Alnylam Pharmaceuticals positions in Q2 2023 and 54 closed out, a net change of +1 holder.
- The largest Alnylam Pharmaceuticals buyer in Q2 2023 was Capital International Investors, an estimated $129M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2023 was Norges Bank, an estimated $162M sold.
Based on aggregated 13F filings for Q2 2023.